Takagi T, Sampi K, Sawada U, Sakai C, Oguro M
Hematology-Chemotherapy Division, Chiba Cancer Center Hospital, Japan.
Int J Hematol. 1993 Jan;57(1):67-71.
To evaluate a new combination chemotherapy with mitoxantrone (MXT), etoposide (VP-16), vindesine (VDS), and prednisolone (MEVP therapy) as a front-line chemotherapy for non-Hodgkin's lymphoma (NHL), a prospective randomized study comparing this therapy (28 patients) with CHOP therapy (29 patients) was conducted in 57 patients with intermediate-grade or high-grade NHL with stages II-IV. The MEVP therapy consisted of 10 mg/m2 of MXT intravenously on day 1, 2 mg/m2 of VDS intravenously on day 1, 200 mg/m2 of VP-16 orally on days 1-3, and 40 mg/m2 of prednisolone orally on days 1-5. This regimen was repeated every 3 weeks for up to 10 courses. Complete responses (CR) were achieved in 17 (63.0%) of the 27 evaluable patients treated with MEVP therapy, and in 20 (71.4%) of the 28 evaluable patients treated with CHOP therapy. Relapse-free survival rates and overall survival rates at 3 years were 58.8% and 46.4%, respectively, for the MEVP group and 70.0% and 54.0%, respectively, for the CHOP group. Granulocytopenia was more severer and associated infection episodes were more frequent in the MEVP group. MEVP therapy was effective as a front-line chemotherapy for intermediate- and high-grade NHL, although it was not superior to CHOP therapy in treatment effect and was not less toxic than CHOP.
为评估米托蒽醌（MXT）、依托泊苷（VP - 16）、长春地辛（VDS）和泼尼松龙（MEVP疗法）的新型联合化疗方案作为非霍奇金淋巴瘤（NHL）一线化疗方案的疗效，对57例II - IV期中级或高级NHL患者进行了一项前瞻性随机研究，比较该疗法（28例患者）与CHOP疗法（29例患者）。MEVP疗法包括第1天静脉注射10 mg/m²的MXT、第1天静脉注射2 mg/m²的VDS、第1 - 3天口服200 mg/m²的VP - 16以及第1 - 5天口服40 mg/m²的泼尼松龙。该方案每3周重复一次，最多进行10个疗程。接受MEVP疗法的27例可评估患者中有17例（63.0%）达到完全缓解（CR），接受CHOP疗法的28例可评估患者中有20例（71.4%）达到完全缓解。MEVP组3年无复发生存率和总生存率分别为58.8%和46.4%，CHOP组分别为70.0%和54.0%。MEVP组粒细胞减少更严重，相关感染发作更频繁。MEVP疗法作为中级和高级NHL的一线化疗有效，尽管其治疗效果不优于CHOP疗法，且毒性不比CHOP小。
